NNI-362
NNI-362 has been studied in 2 papers since 2021: 1 trial in people, 1 in animals. The newest paper, Aug 7, 2025: “First-in-human study of neuron regenerative therapy NNI-362 to evaluate the safety, pharmacokinetics, and pharmacodynamics in healthy aged population”.
2 papers study it5 findingsUpdated
At a glance
The findings reach people, from one lab or study. 2 independent labs in 1 country; 1 trial, none about aging.
“NNI-362, at the two highest multiple doses, significantly reduced plasma p-tau181 levels compared to pretreatment levels (P < 0.0012 to P < 0.0009)”
None of its findings points the other way.
- 2 independent labs in 1 country
- 1 trial, none about aging
- Funders: National Institute on Aging and 1 more
- 5 of 5 findings with company ties
- 1 of 1 trial sponsored by its developers
- Human trial1
- Animals1
Studies in people
1 study gave NNI-362 to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases P-TAU181 | Randomized trialsingle dose or 10-day multiple dose | 56 people50–72 years of ageHealthy aged subjects | Alzheimer's research & therapy, Aug 7, 2025 |
What did studies of NNI-362 find?
4Studies of NNI-362 measured 4 outcomes, among them P-TAU181, cognitive function and neurogenesis.
P-TAU181
downin humans1
1 study
P-TAU181
downin humans1
NNI-362 decreases P-TAU181 in humans.
Human trialplasmasingle dose or 10-day multiple dose
NNI-362 decreases P-TAU181 in humans (healthy, cognitively-unimpaired) (P < 0.0012 to P < 0.0009).
Human trialhealthy, cognitively-unimpairedoral
Cognitive function
upin mice1
1 study
Cognitive function
upin mice1
NNI-362 improves cognitive function in mice (aged mice and Down syndrome-modeled mice).
Animalsaged mice and Down syndrome-modeled mice
Neurogenesis
upin human cells1
1 study
Neurogenesis
upin human cells1
NNI-362 increases neurogenesis in human cells.
Cellsneural progenitor cell
RPS6KB1
upin human cells1
1 study
RPS6KB1
upin human cells1
NNI-362 activates RPS6KB1 in human cells.
Cellsneural progenitor cell
Trial sponsors
Company1 trialPhase 156 people